scholarly journals A REVIEW ON CLINICAL OUTCOMES OF BEMPEDOIC ACID AS ADD-ON THERAPY WITH EZETIMIBE FOR THE TREATMENT OF HYPERLIPIDEMIA

2021 ◽  
Vol 12 (4) ◽  
pp. 1-7
Author(s):  
Raja Vidhya D ◽  
Girija S ◽  
Nila Ganamurali ◽  
Dhivya Dhanasekaran ◽  
Sarvesh Sabarathinam
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cardiovascular Complications ◽  
Quality Analysis ◽  
Cochrane Library ◽  
Low Density ◽  
Statin Intolerance ◽  
Safety And Efficacy ◽  
Beneficial Effects ◽  
Randomized Controlled Studies

Background: Cardiovascular complications are one of the leading causes of global mortality. Statins are intended to produce beneficial effects in reducing the risk of morbidity and mortality in cardiovascular patients. However, it becomes negligible in statin intolerant patients mainly due to muscle related symptoms. Objective: The objective of the study is to summarize the results of the studies available on safety and efficacy of bempedoic acid/ezetimibe combination treatment in statin intolerant patients. Methods: After comprehensive literature survey, in Cochrane Library, PubMed, Embase and Medline, randomized controlled studies involving statin intolerant hyperlipidemia, patients with low- density lipoprotein ≥200 mg/dl and at high risk of cardiovascular disease treated with Bempedoic acid and ezetimibe combination were selected. Results: For final quality analysis two clinical trials were selected to assess the safety and efficacy of the combination of Bempedoic acid and Ezetimibe. Data shows Bempedoic acid and Ezetimibe combination significantly lowered the low-density lipoprotein compared to the control groups (placebo vs Bempedoic acid vs ezetimibe). In addition, the data shows significant reduction in highly sensitive C- reactive protein, non-high density lipoprotein cholesterol, total cholesterol and apolipoprotein B. Conclusion: Overall, we conclude that the combination of Bempedoic acid and Ezetimibe can be considered as a treatment of choice for the treatment of hyperlipidemia for patients with statin-intolerance or maximally tolerated even to low-dose statins.

Effect of Prunus Dulcis & Álpha-Tocopherol in Ethanol Induced Dyslipidemia In Wistar Rats

2020 ◽  
Vol 13 (4) ◽  
pp. 1619-1624
Author(s):  
Samuel Sundar Doss ◽  
J. Vijayakumar ◽  
E. Sukumar ◽  
K. Rekha
Keyword(s):  
Wistar Rats ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Prunus Dulcis ◽  
Alpha Tocopherol ◽  
Control Group ◽  
P Value ◽  
Low Density ◽  
Ethanol Group ◽  
Beneficial Effects

The study is aimed at assessing the effect of Prunus dulcis and alpha-tocopherol treatment against ethanol induced dyslipidemia in Wistar rats. 30 albino Wistar rats were selected based on the selection criteria and equally distributed into 5 groups – Control, ethanol, Prunus dulcis, alpha-tocopherol and combination of alpha-tocopherol + Prunus dulcis treated for 40 days. After the treatment for 40 days, all the animals were euthanized and a retro-orbital puncture was made to collect the blood samples for biochemical investigations. Obtained results were statistically analysed using ANOVA. Compared to ethanol group alpha tocopherol, Prunus dulcis and alpha tocopherol + Prunus dulcis treatment significantly decreased total cholesterol and triglycerides levels with p value <0.001. High density lipoprotein (66.31%) levels in the ethanol group were decreased compared to the control group and were significantly increased in other groups. Low density lipoprotein and Very low density lipoprotein levels were higher in the ethanol group compared with the control group and were significantly reduced in other groups with p value <0.001. Results suggest that ethanol has an ill effect on the lipid profile. Treatment with Prunus dulcius and alpha-tocopherol both solely or in combination has produced beneficial effects against dyslipidemia.

scholarly journals (Pro)renin Receptor Inhibition Reduces Plasma Cholesterol and Triglycerides but Does Not Attenuate Atherosclerosis in Atherosclerotic Mice

2021 ◽  
Vol 8 ◽  
Author(s):  
Dien Ye ◽  
Xiaofei Yang ◽  
Liwei Ren ◽  
Hong S. Lu ◽  
Yuan Sun ◽  
...  
Keyword(s):  
Plasma Lipids ◽  
Inflammatory Responses ◽  
Plasma Cholesterol ◽  
Low Density Lipoprotein ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
Low Density ◽  
Beneficial Effects ◽  
Receptor Inhibition ◽  
Density Lipoprotein Receptor

Objective: Elevated plasma cholesterol concentrations contributes to ischemic cardiovascular diseases. Recently, we showed that inhibiting hepatic (pro)renin receptor [(P)RR] attenuated diet-induced hypercholesterolemia and hypertriglyceridemia in low-density lipoprotein receptor (LDLR) deficient mice. The purpose of this study was to determine whether inhibiting hepatic (P)RR could attenuate atherosclerosis.Approach and Results: Eight-week-old male LDLR−/− mice were injected with either saline or N-acetylgalactosamine-modified antisense oligonucleotides (G-ASOs) primarily targeting hepatic (P)RR and were fed a western-type diet (WTD) for 16 weeks. (P)RR G-ASOs markedly reduced plasma cholesterol concentrations from 2,211 ± 146 to 1,128 ± 121 mg/dL. Fast protein liquid chromatography (FPLC) analyses revealed that cholesterol in very low-density lipoprotein (VLDL) and intermediate density lipoprotein (IDL)/LDL fraction were potently reduced by (P)RR G-ASOs. Moreover, (P)RR G-ASOs reduced plasma triglyceride concentrations by more than 80%. Strikingly, despite marked reduction in plasma lipid concentrations, atherosclerosis was not reduced but rather increased in these mice. Further testing in ApoE−/− mice confirmed that (P)RR G-ASOs reduced plasma lipid concentrations but not atherosclerosis. Transcriptomic analysis of the aortas revealed that (P)RR G-ASOs induced the expression of the genes involved in immune responses and inflammation. Further investigation revealed that (P)RR G-ASOs also inhibited (P)RR in macrophages and in enhanced inflammatory responses to exogenous stimuli. Moreover, deleting the (P)RR in macrophages resulted in accelerated atherosclerosis in WTD fed ApoE−/− mice.Conclusion: (P)RR G-ASOs reduced the plasma lipids in atherosclerotic mice due to hepatic (P)RR deficiency. However, augmented pro-inflammatory responses in macrophages due to (P)RR downregulation counteracted the beneficial effects of lowered plasma lipid concentrations on atherosclerosis. Our study demonstrated that hepatic (P)RR and macrophage (P)RR played a counteracting role in atherosclerosis.

scholarly journals Biphasic Regulation of Lipid Metabolism: A Meta-Analysis of Icodextrin in Peritoneal Dialysis

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Yan-Feng Huang ◽  
Da-Jian Zhu ◽  
Xiao-Wu Chen ◽  
Man-Zhao Ouyang ◽  
Wei-Jie Zhang
Keyword(s):  
Lipid Metabolism ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Biomedical Literature ◽  
Lipoprotein Cholesterol ◽  
Cochrane Library ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
The Impact

Objectives. The objective of this systematic meta-analysis was to study the impact of icodextrin (ICO) on lipid profiles.Methods. MEDLINE, PubMed, Embase, Chinese Biomedical Literature, and the Cochrane Library and Reference lists were searched (last search September 2014) in accordance with the Cochrane Handbook for Systematic Reviews of Interventions.Results. Searches identified 13 eligible trials with a total of 850 patients. The differentials of total cholesterol (TC) and free fatty acid (FFA) in the ICO group were greater than those in the GLU group. Metaregression analysis showed that TC levels positively correlated with its baseline levels. In the subgroup of patients with dialysis duration more than 6 months, TC and TG in the ICO group were less. In pooled data from cross-sectional studies, differential of TG in the ICO group was less. In the subgroup of patients with diabetes (Martikainen et al., 2005, Sniderman et al., 2014, and Takatori et al., 2011), differential of high-density lipoprotein cholesterol (HDL-C) in the ICO group was less. There was no significant effect on low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), or lipoprotein(a).Conclusions. ICO may be beneficial to lipid metabolism, especially for its biphasic regulation of plasma TC levels.

Sign in / Sign up

Export Citation Format

Share Document